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Abstract
Mutations in theMTM1 gene cause X-linked myotubular myopathy (XLMTM), characterized by neonatal hypotonia and respiratory failure, and
are responsible for a premature mortality in affected males. Female carriers are usually asymptomatic but they may present with muscular
weakness because of a hypothesized skewed pattern of X-chromosome inactivation.
By combining next generation sequencing (NGS) and CGH array approaches, we have investigated the role of MTM1 variants in a large cohort
of undiagnosed patients with a wide spectrum of myopathies. Seven novel XLMTM patients have been identified, including two girls with an
unremarkable family history for myotubular myopathy.
Moreover, we have detected and finely mapped a large deletion causing a myotubular myopathy with abnormal genital development.
Our data confirm that the severe neonatal onset of the disease in male infants is sufficient to address the direct molecular testing toward the
MTM1 gene and, above all, suggest that the number of undiagnosed symptomatic female carriers is probably underestimated.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
Keywords: X-linked myotubular myopathy; MTM1 gene; Abnormal genital development; Next-generation sequencing; CGH array
1. Introduction
Centronuclear myopathies (CNMs) are congenital myopathies
characterized by the presence of nuclei in the central part of the
muscle fibers [1]. Four genetically different types have been
described so far: an autosomal dominant form caused by
mutations in the DNM2 gene [2]; an autosomal dominant or
recessive form related to mutations in the BIN1 gene [3,4]; an
autosomal dominant or recessive form caused by mutations
in the RYR1 gene [5]; and an X-linked myotubular myopathy
(XLMTM) due to mutations in the MTM1 gene [6].
The MTM1 gene comprises 15 exons and codes for
myotubularin, a phosphatase targeting specifically PtdIns3P
and PtdInsP2, two phosphoinositides (PIs) involved in the
endosomal–lysosomal pathway [7,8]. Myotubularin is essential
for muscle cell differentiation and regulates the mitochondrial
morphology in muscular fibers by a direct interaction with
desmin [9].
In 1996, mutations in the MTM1 gene were identified as
causative of the XLMTM condition, characterized by a variable,
but usually severe, phenotype [6]. Hypotonia at birth, muscle
weakness and respiratory failure causing a neonatal mortality
occur in the most severe cases [10]. Its prevalence is nearly
1/50,000 males and female carriers are usually asymptomatic
[11]. However, a number of carriers, manifesting a milder
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phenotype probably due to a skewed X inactivation, have been
described. Considering the broad range of phenotypes caused
by MTM1 mutations, the presence of necklace fibers at muscle
biopsy is a hallmark of this specific disease as well as of a
DNM2 related myopathy [12–14].
As evidenced in recent mutation screenings of MTM1, small
variants, including missense, nonsense and splice site single
base changes, represent the largest proportion (93%) of causative
mutations in this gene [11,15]. In particular, some missense
mutations are correlated to a milder phenotype and most nonsense
variants or rare large deletions cause a severe condition.
Here we describe seven novel patients with causative point
mutations in the MTM1 gene and a family with a large deletion
on the X chromosome, detected by performing a next generation
sequencing (NGS) approach [16] and a customized CGH array
analysis [17] in a large cohort of undiagnosed patients with a
wide spectrum of myopathies.
2. Materials and methods
2.1. Sample collection
For the NGS screening, 504 DNA samples from patients
(59.6% males) with a wide spectrum of myopathies, including
a congenital myopathy (32.5%), a limb-girdle muscular dystrophy
(LGMD - 51.3%) or other clinical conditions (16.2%, comprising
distal myopathy, isolated hyperckemia and metabolic myopathy)
were collected. A written informed consent was signed by
patients, according to the guidelines of Telethon Italy and as
approved by the Ethics Committee of the “Seconda Università
degli Studi di Napoli”, Naples, Italy. More than 90% of samples
collected had previously been tested unsuccessfully, according
to the observed phenotype.
In 105 patients without any significant variant detected by
NGS, a CNVanalysis by a customCGHarraywas also carried out.
2.2. Molecular analysis
Genomic DNA was extracted from the peripheral blood by
phenol/chloroform extraction.
For the NGS screening, the samples were enriched using the
MotorPlex assay, as previously described [16]. In all the
samples analyzed, all the exons of the MTM1 gene and the 10
flanking bases were sequenced at a coverage >20×.
The raw data obtained were analyzed using an in-house
pipeline described elsewhere [16,18].
MTM1 mutated exons were amplified by PCR using M13-
tailed primers. M13 primers were used to perform Sanger
sequencing using an ABI PRISM 3130 XL automatic DNA
Sequencer Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA).
For the detection and characterization of copy number variants
involving the MTM1 gene, a custom CGH array, named Motor
Chip v3 and able to investigate more than 400 genes related to
neuromuscular disorders with an exonic resolution [17], was
used. For a refinement of the deletion detected in family VI, an
ISCA v2 array was employed. CGH analyses were performed
according to the manufacturer’s instructions (Agilent Technologies,
Santa Clara, CA, USA).
To test for skewed X-chromosome inactivation, two
heterozygous microsatellites mapping on the X-chromosome
(DXS8020 and DXS8015, Linkage mapping set, Applied
Biosystems) were analyzed using genomic DNA from blood,
muscle and buccal swab after restriction digestion with the
methylation-sensitive enzyme HpaII.Analysis of the PCR products
was performed on an Applied Biosystem 3130xl automated
sequencer. The X inactivation pattern was defined as random
at ratios 50:50, <80:20, and skewed at ratios ≥80:20 as described
elsewhere [19,20].
2.3. Muscle imaging, histological studies and western blot
analysis
Lower limb MRI was performed in 1.5-T MR scanners as
previously described [21].
Biopsies were investigated according to standard procedures
[22].
For Western blot (WB) analysis skeletal muscles were
homogenized in 50 mM Tris–HCl, pH 7.5, 50 mM NaCl, 10%
(% v/v) glycerol, 1% (% v/v) Triton X-100 containing inhibitors
of proteases (Sigma Aldrich). Samples of total protein (50 μg)
were loaded and separated on 8% SDS–PAGE. Immunolabeling
of the MTM1 gene product (myotubularin) was performed by
using a mouse monoclonal antibody (1:250; Abnova, Taipei
City, Taiwan). The anti-GAPDH antibody (1:10,000) used as
an internal control was purchased from Abcam (Cambridge,
UK); peroxidase-conjugated anti-mouse IgG was used as a
secondary antibody (Jackson ImmunoResearch, PA, USA).
Reactive bands were detected using the Immobilon Western
Chemiluminescent HRP Substrate detection kit (Millipore
Corporation, Billerica, MA, USA).
3. Results
3.1. Next generation sequencing screening
To reveal the frequency of rare MTM1 gene variants in 504
myopathic patients, we analyzed the results of a targeted
resequencing study [16]: in particular, we detected 3 variants of
unknown significance (VOUS – Supplementary Table S1) and 5
pathogenic variants in MTM1.
The c.176T>C, p.Ile59Thr was found in a female patient
who presented hyperckemia and also harbored an additional,
well-known, pathogenic mutation in theDYSF gene. The variant
is listed in the ExAC database which includes 3 hemizygous
individuals, reducing the possibility of a pathogenicity of this
variant.
The c.1475C>T, p.Thr492Ile was detected in a healthy
mother, investigated as a control in a trio analysis. Even if the
variant is not present in large databases, it is predicted to be
benign or neutral in 3 out of 4 programs used and the amino
acid is not conserved during evolution.
The c.481G>A, p.Val161Met was detected in a 25-year-old
male with a LGMD phenotype in which no further causative
variants had been identified. The variant is rare (a single
heterozygous individual in ExAC) but the amino acid is not
conserved during evolution.
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Among the 5 pathogenic variants, 4 nonsense mutations
and a missense variant were identified (Table 1): two variants
(c.1558C>T and c.757C>T) have already been reported [23–25],
whereas the other three (c.118G>T, c.1115T>A and c.1150C>T)
are novel.
3.2. Clinical data
All of the three male XLMTM patients identified had a
similar, typical early and severe phenotype.
In particular, case II showed early neonatal hypotonia,
requiring immediate respiratory support with continuous
positive airway pressure and naso-jujenal feeding. Muscle
biopsy revealed uniformly small myofibers and numerous fibers
containing large, centrally located nuclei (75%). Some fibers
contained central areas with either an excessive basophilic
staining or a clearing of the cytoplasm, which correspond to
aggregates of organelles on histochemical stains for reduced
nicotinamide adenine dinucleotide (NADH) and cytochrome
oxidase (COX). Central nuclei were found in both fiber types,
and there was no evidence of grouping or other fiber type-
specific changes on ATPases staining.
The second patient (IIIa) was a floppy baby who presented
at birth respiratory distress and feeding difficulties. His muscular
biopsy revealed fiber size variability and 30–35% of the fibers
containing a single central nucleus (Fig. 1a,b). We also identified
two manifesting carriers in the family: the 30-year-old mother
(IIIb) who has complained of mild axial and facial muscle
weakness since childhood and shows elongated face and low
set ears; and the 62-year-old maternal grandmother (IIIc) who
has complained of mild muscle weakness since age 40 and has
a waddling gait and mild facial, neck extensor muscle and
mild proximal limb muscle weakness.
The last patient (case IV) was a newborn with a congenital
hypotonic disorder referred to as possible myotubular myopathy.
His family showed an X-linked pattern of inheritance, since
three maternal uncles had reportedly early hypotonia and had
died as neonates. In case IV we detected a nonsense variant in
exon 9 (c.757C>T p.Arg253X) inherited from his mother.
More interestingly, we also identified two girls with a sporadic
myopathy and an unremarkable family history for possible
MTM1-related conditions or other neuromuscular disorders.
Case I is a 44-year-old Italian woman, who has had, since
childhood, mild leg weakness, difficulties in climbing stairs
and in squatting and a characteristic tip-toe walking. Seven
years ago, retraction of the Achilles’ tendons was noted. Latest
neuromuscular examination (July 2014) showed a facial weakness,
blepharoptosis, a mild deficit of the orbicularis oculi muscles
and a normal ocular motility. She also had hypotrophy of the
anterior leg muscles and hypertrophy of the calves, mild retractions
at the elbows and hips and a severe lumbar lordosis. Her
muscle weakness was in part asymmetric, as she was significantly
weaker in the muscles in her left arm and leg.
Muscle biopsy evidenced myopathic changes with several
central nuclei and a normal expression of dysferlin and
caveolin. Mutations in the DMPK gene, causing the myotonic
dystrophy type 1, were excluded. Muscle MRI evidenced a
severe fatty infiltration in the scapular girdle, biceps, paraspinal
and abdominal muscles; a less severe infiltration of the thigh
adductors and minimum and medium glutei; a more severe
involvement of the anterior thigh region than the posterior; and,
finally, severe fat substitution of the leg muscles (the right
soleus and left medial gastrocnemius).
Patient V is a 6 year old girl from Sardinia. Her birth was
uneventful but feeding difficulties appeared later. Her motor
development was slightly delayed, although she could walk at
Table 1
List of patients.
ID Sex Age of
onset
Age of
death
Severity Transmission Histological features CK levels Mutation References
I Female Childhood – Intermediate Sporadic Several central nuclei Normal c.118G>T,
p.(Gly40X)
Novel
II Male Birth 3 mo. Severe Sporadic Small myofibers and a numerous fibers
containing large, centrally located nuclei
(75%)
Normal c.1558C>T,
p.(Arg520X)
Described
(Ref. [23])
IIIa Male Birth 3 wks Severe Dominant/
X-linked
More than 50% of fibers with myotubular
appearance, marked predominance of type I
fibers
Normal c.1150C>T,
p.(Gln384X)
Novel
IIIb Female Childhood – Mild Few fibers with central nuclei marked
predominance of type I fibers
Normal
IIIc Female 40 yrs – Intermediate Few fibers with central nuclei marked
predominance of type I fibers , small type
grouping
Normal
IV Male Birth 2 mo. Severe X-linked Several central nuclei n.a. c.757C>T,
p.(Arg253X)
Described
(Refs. [24,25])
V Female Infancy – Intermediate Sporadic Variability in fiber diameter with several
central nuclei and necklace fibers
slightly
elevated
c.1115T>A,
p.(Leu372His)
Novel
VI Male Birth n.a. Severe X-linked n.a. n.a. Interstitial
deletion at
Xq28
Novel
n.a. = not available; mo. = months; wks = weeks; yrs = years.
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18 months. She also had mild speech delay.At the age of 3 years
she was very clumsy and hypotonic.
Neurological examination at 5 years revealed a myopathic
face, with a triangular mouth and a divergent strabismus in the
right eye. Both proximal and distal weaknesses were present
with joint hyperlaxity in her hands. Her tendon reflexes were
reduced. She could rise from the floor with the Gowers maneuver
and she could not run or jump. She had flat feet and mild
scoliosis. Her nerve conduction velocities were normal and the
EMG was consistent with myopathic damage. Her CK levels
were slightly elevated (200 U/L).
Her muscle biopsy (Fig. 1c,d) showed a great variability in
fiber diameter, an increase of connective-adipose tissue, the
presence of several central nuclei and rare necklace fibers [12].
An asymmetric pattern was observed in the MRI with the
tibialis anterior and soleus affected on the left side (Fig. 2a).
The de novo missense variant identified in patient V results in
a reduction of the protein expression (Fig. 2b), corroborating
its presumable pathogenicity. Interestingly, a similar protein
reduction was observed in a female patient previously reported
(patient 33 in Ref. [15]) with a de novo heterozygous variant
causing a misplicing.
3.3. Motor Chip screening for the CNV identification
involving the MTM1 gene
One hundred and five samples of patients without any
significant variant detected by NGS were also analyzed by a
custom CGH array, termed Motor Chip [17], but none showed
a deletion or duplication involving the MTM1 gene.
We detected a deletion of the chromosomal region comprising
the MTM1 gene in DNA from a healthy woman who had
sought prenatal counseling to assess the risk of recurrence for
a complex phenotype that had been observed in her first son.
This child had shown, after delivery, a very severe phenotype,
including general hypotonia, an ogival palate, hypospadias,
scrotal hypoplasia, a single umbilical artery, camptodactyly
and clubfoot. At counseling, a written report evidencing an
entire deletion of the MTM1 gene detected by MLPA was
Fig. 1. Muscle biopsies of cases IIIa and V. Muscle biopsy from patient IIIa: Hematoxylin–eosin stain (HE) (a) shows a muscle fiber size variability and many fibers
(30–35%) contain a single central nucleus. ATPase 4.6 stain (b) reveals also a type 1 fiber predominance and atrophy; in particular, many fibers show a central area
with a reduced myofibrillar reaction. A marked fiber size variation, several small fibers with internal nuclei and an increase of connective-adipose tissue have been
observed in the HE stain (c) of a muscle biopsy from patient V. At NADH staining (d) several fibers display radial strands and internal dark ring necklace fibers.
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provided. We identified a heterozygous deletion at Xq28
encompassing MTM1 and additional genomic regions in the
DNA from the mother (minimum deletion region: chrX:
149591931–149841591; maximum deletion region: chrX:
149526823–149844072) (Fig. 3a). The deletion included the
MAMLD1 (CXORF6 or F18) gene, already described as part
of a contiguous gene syndrome in two unrelated children [26,27]
who presented at birth with hypotonia and abnormal genitalia.
The association of this syndromic muscular phenotype has
later been corroborated in two further independent cases [28,29].
Thus our description represents the fifth large deletion on Xq28
(Fig. 3b).
4. Discussion
MTM1 mutations are associated with the X-linked
myotubular myopathy-1, a congenital myopathy, with typical
histological findings of central nuclei, hypotrophy and a
predominance of type I fibers.
A neonatal onset of the disease, as further corroborated by our
investigations, in a male newborn should be sufficient to lead
clinicians toward a hypothesis of an X-linked myotubular
myopathy and to request a direct MTM1 analysis. Similarly, the
presence of a congenital myopathy with anomalies of the genitalia
should always address the testing toward a CNV analysis.
Our large NGS screening had been preceded by gene-specific
tests in agreement with the clinical and histological findings. It
is reasonable to think that, for most male patients with a very
early severe onset, the MTM1 gene will have already been
analyzed: only patients negative at this first tier screening will
have been referred to our center, justifying the low number of
positive patients identified. On the other hand, family III is
quite particular: male patient IIIa, showing a severe congenital
myopathy and a premature death, had an affected mother (IIIb)
and an affected maternal grandmother (IIIc). His family history
may have initially suggested an autosomal dominant transmission
with anticipation in alternative to an X-linked condition and
precluded direct gene testing.
Fig. 2. Imaging andWB of case V. In patient V (a), most muscles are affected asymmetrically (sn > dx) with only the adductor longus relatively spared. At leg level,
the tibialis anterior and soleus muscles are affected on the left side. Immunolabeling and relative quantification of the MTM1 gene product (b) show a reduced band
in patient V compared to the controls.
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The identification of two (I, V) female patients with MTM1
mutations in the absence of affected males represents an
important result highlighting the need for a broad multigene
study. Even if several different symptomatic carriers of MTM1
variants have been described in the literature (Table 2), their
detection usually derived from the diagnosis of an affected
male, as in the case of IIIb and IIIc.
Moreover, a skewed X-inactivation has been considered as
the cause of the phenotype in female carriers. However, a
re-evaluation of the previously published data seems not to
support this hypothesis: in the 5 year old girl with hypotonia
and general weakness, described by Schara et al. [34], a unilateral
X-inactivation was detected in the muscles but not in the blood;
eight females showed a random expression [32,33,35–38]; and
in only 5 cases was a skewed expression confirmed in the
blood [19,30,31,35,37]. In addition, in our case V, a skewed
inactivation was not observed (ratio < 60:40).We also reevaluated
the X-inactivation in a female patient, already published in a
previous paper (patient 33 in Ref. [15]), detecting a random
inactivation (ratio < 60:40). It is anyway reasonable to assume
that the skewed X-inactivation may be at least one of the
reasons leading to the presence of manifesting carriers but
other epigenetic factors may be involved in the X inactivation
of the normal allele.
However, the penetrance of XLMTM in females is reported
to be lower than that of other muscular disorders, such as the
Duchenne and Becker muscular dystrophies in which 22%
of female carriers are symptomatic or the Emery-Dreifuss
muscular dystrophy where 18% of female carriers have ECG
abnormalities [39].
On the other hand, our study evidences that the frequency
of symptomatic female carriers may be underestimated. All of
the female patients with MTM1 mutations included in the
paper showed histological features related to a centronuclear
myopathy, confirming previous published data [15]. Nowadays,
however, NGS screenings represent a straightforward approach
that is revolutionizing the genetic diagnosis also in the field of
neuromuscular disorders [16,40]. Therefore, large NGS panels
may be considered useful tools to identify sporadic female
XLMTM and the MTM1 gene should always be included in
any NGS test performed for the diagnosis of neuromuscular
disorders.
Even if our Motor Chip analyses did not evidence any variant
in the gene, the possible presence of a heterozygous deletion or
duplication, accounting for about 7% of MTM1 defects [11]
should be always considered because of the NGS limitation in
detecting heterozygous CNV. Moreover, considering the low
penetrance of mutated alleles in females, any variant identified in
the MTM1 gene in the NGS analyses represents an incidental
finding which should be reported to the patient.
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